PureTech Health plc (PRTC) Earnings Call Transcripts

PureTech Health plc's Latest Earnings Call - April 29, 2026

In the first quarter of 2026, PureTech Health plc reported revenues of $4.7 million, slightly down from $4.8 million in 2025, while the company experienced a net loss of $110.1 million compared to a net income of $27.8 million in the prior year. Management emphasized a refined strategy focusing on operational efficiency and capital discipline, with plans to streamline operations and enhance shareholder returns. The company maintained its cash runway guidance through at least the end of 2028, indicating a conservative approach to financial management amidst ongoing clinical developments.

Reported metrics

Guidance from management

Management maintained its cash runway guidance through at least the end of 2028, emphasizing a conservative approach to financial management and operational efficiency.

What management said

Myles, thanks for joining. Yes, no, absolutely. As you say, it's at least through 2028, and that reflects the conservative approach that we take to cash runway. So as you say, we don't factor in any realizations into that cash guidance, and we are assuming commitments into SLA and also support for Gallop as well in that runway guidance.

Absolutely, Miles. Obviously, we're limited in what we can say at the moment about Seaport given that they're on file for IPO in the U.S. But it is our general practice with founded entities that we don't take board seats once they IPO. And that is a general approach that we've taken in the past and we would expect to be taking going forward. It's also the case that we do have royalties beyond just the GLP applicatio...

What analysts pressed on

Analysts expressed concerns regarding the potential impact of rising costs in clinical trials, particularly for Celea, and the lack of expected financial returns from legacy holdings, which may affect the overall valuation of PureTech.

Main topics on the call

• Operational Strategy Refinement — Management outlined a refined strategy aimed at improving execution and capital discipline, stating, "We intend to operate a significantly leaner and more efficient hub." This approach is expected to enhance shareholder ...
• Celea Therapeutics Fundraising Progress — Celea is nearing completion of its fundraising, with management indicating they have made "very substantial progress" and have a "clear line of sight to getting this done." This funding is crucial for advancing their Pha...
• Gallop Oncology Clinical Data — Gallop announced positive top-line data for LYT-200 in a Phase Ib trial, with management noting, "LYT-200 had an excellent safety profile with no dose-limiting toxicities." This positions Gallop favorably for future tria...
• Cash Runway Guidance — PureTech confirmed its cash runway extends at least through the end of 2028, with management stating, "We expect to have operational runway at least through the end of 2028." This guidance reflects a conservative financi...

Read the full PureTech Health plc transcript (April 29, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 31 PureTech Health plc earnings call transcripts on record, spanning August 27, 2020 to September 22, 2026. Based on this history, PureTech Health plc reports quarterly. The most recent call on file is dated September 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PRTC

Exchange

LSE

Country

GB

Sector

Health Care

Industry

Biotechnology

Calls on record

31

First call

August 27, 2020

Most recent

September 22, 2026

Reporting cadence

quarterly